InnoPharmax Inc. (4172.TWO)

TWD 15.75

(1.94%)

Market Cap (In TWD)

1.69 Billion

Revenue (In TWD)

46.07 Million

Net Income (In TWD)

-70.83 Million

Avg. Volume

235.7 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
14.4-29.25
PE
-15.44
EPS
-1.02
Beta Value
0.727
ISIN
TW0004172002
CUSIP
-
CIK
-
Shares
107576000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Weihua Hao
Employee Count
-
Website
https://www.innopharmax.com
Ipo Date
2012-09-13
Details
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson's disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation. The company was founded in 1994 and is based in Taipei, Taiwan.